Welcome to our dedicated page for Tabula Rasa Heal news (Ticker: TRHC), a resource for investors and traders seeking the latest updates and insights on Tabula Rasa Heal stock.
Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) is a leading healthcare company that specializes in personalized, comprehensive care for value-based care organizations. The company offers innovative service models and cutting-edge healthcare technology solutions that improve patient outcomes and maximize provider efficiency. Headquartered in Moorestown, New Jersey, TRHC focuses on optimizing medication management and delivering precise, individualized care to at-risk populations.
TRHC's core services include comprehensive pharmacy services, personalized medication management, and a suite of clinical and business management tools. These tools help health plans and provider groups optimize utilization and improve patient health. The company's technology-enabled solutions are designed to reduce risk, enhance medication efficacy, and improve overall healthcare efficiencies.
In recent developments, TRHC has entered into a definitive agreement to be acquired by Nautic Partners for $10.50 per share in cash, valuing the company at approximately $570 million. This acquisition is set to combine TRHC with ExactCare Pharmacy, another portfolio company of Nautic, enhancing the reach and capabilities of both entities. The merger is expected to close in the fourth quarter of 2023, subject to customary closing conditions.
TRHC's recent financial performance has been strong, with significant organic growth in its core PACE (Program of All-Inclusive Care for the Elderly) market. The company has focused on developing and expanding partnerships with risk-bearing healthcare organizations, aiming to serve the most complex care needs. This strategic focus has led to impressive financial results and increased profitability.
For those interested in the latest updates, TRHC will hold a conference call and webcast to discuss its second quarter 2023 financial results on August 8, 2023. The company continuously updates its stakeholders through its Investor Relations section on its website, providing access to financial results, earnings calls, and other significant announcements.
Tabula Rasa HealthCare (TRHC) has scheduled a conference call and webcast for May 9, 2023, at 8:30 a.m. EDT to discuss its first quarter 2023 financial results. The financial results will be released after market close on May 8, 2023. TRHC focuses on medication safety solutions, utilizing proprietary technology like MedWise® to optimize medication regimens, minimize adverse drug events, and reduce healthcare costs. Their clinical tele-pharmacy network enhances patient care nationwide, and their services are trusted by health plans and at-risk provider groups for value-based care initiatives.
Tabula Rasa HealthCare (TRHC) has appointed Brian Adams as President and Chief Executive Officer, effective immediately. Adams, who was previously interim CEO, will also join the Board of Directors. Richard W. Rew II has been named Chief Legal Officer and Corporate Secretary, effective April 10, 2023. The company announced preliminary unaudited revenue for Q1 2023, expected to be between $87.0 million and $88.5 million, exceeding prior guidance of $82 million to $84 million. The company plans to report full financial results in early May. The new leadership aims to advance solutions for the Program of All-Inclusive Care for the Elderly (PACE) market and improve patient care.
Tabula Rasa HealthCare (TRHC) reported a strong fourth quarter for 2022, achieving $82.7 million in revenue, a 20% increase year-over-year. Despite this growth, the company recorded a GAAP net loss of $18.4 million, up from $13.0 million the previous year. Full-year revenue reached $299.5 million, a 15% increase, but the net loss grew to $77.3 million. The company has made strategic moves, including leadership changes and the divestiture of non-core businesses, to focus on sustainable growth. Looking ahead, TRHC projects revenue for 2023 to be between $343 million and $354 million, with adjusted EBITDA guidance of $17 million to $20 million.
Cureatr has acquired SinfoníaRx from Tabula Rasa HealthCare (NASDAQ: TRHC), enhancing its medication therapy management (MTM) services. This acquisition is expected to strengthen Cureatr's clinical pharmacy offerings and expand its team, improving medication management for health plans and patients nationwide. The integration aims to reduce healthcare costs and enhance patient experience through innovative programs. Cureatr's existing platform, Meds 360°, will leverage SinfoníaRx's technology and expertise to address the $528 billion medication management issue in the U.S. The acquisition aligns with Cureatr's mission to provide essential clinical pharmacist services to patients.
FAQ
What is the market cap of Tabula Rasa Heal (TRHC)?
What does Tabula Rasa HealthCare, Inc. do?
Where is Tabula Rasa HealthCare headquartered?
What recent acquisition involves Tabula Rasa HealthCare?
What are the core services provided by TRHC?
How does TRHC improve patient care?
What is PACE and how is TRHC involved?
What were TRHC's recent financial results?
When is TRHC's next financial results call?
What is the significance of TRHC's merger with ExactCare Pharmacy?
How can investors stay updated on TRHC's latest news?
